Introduction: Increased tuberculosis prevalence, and isolation of multidrug resistant (MDR) Mycobacterium tuberculosis strains frequently as causative organisms from tuberculosis infections are resulted in increasing need of new anti-tuberculosis drugs. Nowadays, fluoroquinolones known to have fewer side effects than the other drugs used in treatment of tuberculosis are sometimes assessed even as first-line anti-tuberculosis drugs due to their in vitro and in vivo strong activity. It was aimed in this study to investigate phenotypically the fluoroquinolone susceptibility in MDR and non-MDR M. tuberculosis isolates.
INtrODUctION
Mycobacterium tuberculosis that causes tuberculosis (TB) is the world's most widespread and oldest public health problem, especially in Asian and African countries. It is reported that currently about one third of the world is infected with M. tuberculosis. Resistance and high HIV prevalence, mostly due to the treatment of TB with medication, are the most important problems in controlling TB. Drug resistance rates and TB incidence are the most needed data to provide control of this disease (1) (2) (3) (4) (5) . Isoniazid (INH), rifampicin (RIF), ethambutol (ETB) and pyrazinamide (Pz) are the first choice drugs in TB treatment. M. tuberculosis isolates that are "least resistant to INH and RIF" are defined as multi-drug resistant (MDR). The emergence of MDRs is an important problem that makes TB treatment difficult. Depends on the increase in MDR-TB cases and the difficulties in treatment, second-line medications were needed. Due to the irregular and inappropriate use of the drugs in the treatment, extended drug resistant (XDR) M. tuberculosis isolates, which are resistant to one of quinolone and parenterally used medicines (kanamycin, capreomycin, amikacin) besides INH, RIF resistance, have begun to be observed as well as the MDR isolates (3, (6) (7) (8) .
Fluoroquinolones (FQs) are a widely-favoured broad-spectrum group used for the treatment of respiratory, gastrointestinal and urinary tract infections, osteomyelitis and sexually transmitted infections, especially. Demonstration of in vitro and in vivo efficacy of FQs against M. tuberculosis ensured that these drugs were also included in the treatment of TB. FQs rarely cause serious side effects than other drugs used for the treatment of TB, they are suitable to provide the appropriate dosage range and is also advantageous because of high bioavailability. Ciprofloxacin (CIP) and ofloxacin (OFX) is at least effective against TB bacilli, levofloxacin (LEV), gatifloxacin (GTX), moxifloxacin (MXF), and sparfloxacin (SPX), which is reported as the most effective FQs. It is also stated that powerful FQs such as MXF and LEV may be considered as first-line drugs to shorten the duration of treatment in susceptible cases (6, (9) (10) (11) (12) . FQs exhibit bactericidal effects against M. tuberculosis via the DNA gyrase enzyme, a Type II topoisomerase encoded by gyrA and gyrB genes. FQ resistance in M. tuberculosis has been observed to be a consequence of the presence of mutations, low cell wall permeability, and efflux pump systems in or around the "quinolone resistance determining region (QRDR)" on gyrA/gyrB in general (6, (9) (10) (11) (12) (13) (14) .
In this study, it was aimed to investigate phenotypically the resistance against FQ antibiotics CIP, LEV and MOX by agar proportion method in MDR and non-MDR M. tuberculosis isolates from various clinical specimens in the Aegean region of Turkey. Research Hospital, Medical Microbiology Laboratory were studied. Seventy nine (62.7%) of these isolates were MDR. FQ susceptibilities in the isolates were phenotypically determined by the agar proportion method in accordance with the Clinical and Laboratory Standards Institute (CLSI) recommendations (15). Stok solutions of CIP (Koçak Farma, Turkey), LEV (Sanofi Aventis, Turkey) and MXF (Bayer AG, Turkey) were prepared and sterilised by filtration. Middlebrook (MB) 7H10 agar (BD & Difco) supplemented with 10% oleic acid, albumin, dextrose and catalase (OADC) was used as a growth medium. The dehydrated medium was prepared and autoclaved according to the manufacturer's recommendations. The OADC solution and two-fold dilution series of antibiotic solutions were added to the sterilized medium, kept at 50-55°C in a water bath, and allowed to solidify after poured into separated plates. Antibiotic-free medium were also prepared for growth control. The isolates were adjusted to a McFarland No: 1, and then diluted to 10 -2 ve 10 -4 . Antibiotic-free (control) and antibiotic media were inoculated with 100 μL of dilutions of bacterial suspensions. Plates were wrapped in parafilm and incubated for three weeks in an incubator with a CO 2 ratio of 5% at 37°C. The concentration of antibiotic in the plate, which inhibited more than 99% of the growth compared to the control, was accepted as the minimal inhibitor concentration (MIC) for that strain [Breakpoints: CIP (> 2 µg/mL), LEV (> 1 µg/mL), MXF (> 0.5 µg/mL)]. M. tuberculosis H37Rv (ATCC 27294) was used as a control strain in the study.
MAtErIALS and MEtHODS

rESULtS
Among the M. tuberculosis strains, 47 non-MDR isolates were all sensitive to CIP, LEV and MXF. On the other hand, among the 79 MDRs, 12 (15.2%) isolates were found to be resistant to CIP, 5 (6.3%) isolates resistant to LEV and 4 (5.1%) isolates resistant to MXF. CIP, LEV and MXF sensitivity ratios, MIC ranges (μg/ mL), MIC 50 and MIC 90 values for M. tuberculosis strains were given in Table 1 .
DIScUSSION
Tuberculosis, mainly due to migration from endemic regions, HIV epidemics and the presence of MDR M. tuberculosis isolates, has increased again since the 1980s. Today, it continues to be important as an infectious disease that has problems in control and results in high mortality, despite the improvement of diagnosis and treatment methods. The recognition of the treatment and resistance mechanisms of MDR-TB patients is accepted as a fundamental component of TB control. In countries with high TB incidence, high rates of resistance also indicate a relationship between incidence and resistance (2, 14, 16) . In recent years, about 2-64% of MDR M. tuberculosis has been reported between 2000 and 2014 in different countries of the world and in different regions of our country. It is also stated that the rate of MDRs is low in new cases but it can be increased because of the use of antibiotics in patients who have already received TB treatment (1, 2, 4, 5, (16) (17) (18) (19) .
Resistance in M. tuberculosis causes from natural resistance genes or spontaneous mutations. It is not possible to transfer the resistance genes or plasmids among these bacteria (2) . FQ resistance in M. tuberculosis is thought to be led to primarily by gyrA mutations, then by drug permeability reduction and by efflux pump systems. Cross resistance against FQs and sometimes different group antibiotics can be seen in M. tuberculosis in consequence on common resistance mecha- nisms (9, 18, (20) (21) (22) . In a study comparing the efficacy of MXF, GTX and OFX on M. tuberculosis, MFX and GTX were found to be more effective than OFX, and cross resistance against these antibiotics were determined. It was stated that an isolate resistant to the all three FQs with no mutation in the gyrA or B, probably had different resistance mechanisms (22) . Escribano et al. (2007) showed efflux pump systems effective for both FQ and linezolid resistance in M. tuberculosis (20) . Since FQs are commonly used against resistant M. tuberculosis, acquired FQ resistance is often associated with resistance to RIF and other first-line drugs.
A study in Taiwan found that there was an association between resistance to FQ and resistance to any of the first-generation TB medicines, except streptomycin, and that this association was stronger in MDRs. The rate of FQ resistance was reported to be 3.3% when 420 M. tuberculosis isolates selected from the 2004-2005 period were considered and 19% when only the MDR cases were evaluated. Susceptibilities of CIP, LEV, MXF of the isolates were indicated as 98.6%; 98.6%; 97.6%, respectively. In another study, the rate of OFX resistance in the isolates from 640 patients in the USA between 2002 and 2006 was 2.5%. In addition, it has been reported that the use of FQ for more than 10 days, especially 60 days before the diagnosis of TB for any reason, may cause FQ resistance in M. tuberculosis (21) . In a study about MDR M. tuberculosis in Pakistan, FQ resistance was tested using CIP between the isolates from 2005-2008, and OFX beginning from 2009. The reported rates of FQ resistance were increased from about 17.41% to 42.92%, and it was declared that this increase might be due to uncontrolled and irregular use of FQ for the treatment of TB or other infections (24) . As opposed to the studies which claim that previously usage of FQs or longer exposure due to any infection causes resistance in M. tuberculosis, Wang et al. (2007) (18) stated in their study these factors did not affect FQ susceptibility.
Patients whose strains in our study have been isolated have not been able to obtain any information on FQ exposure and duration in previous periods. However, according to our data, whereas there is no FQ resistance in non-MDRs, its presence in MDRs, supports the idea that to being MDR would be a factor that increases the tendency to FQ resistance.
In this study, quite good susceptibility results were determined for CIP nearly over 80%, and for LEV and MXF over 90%. Similarly, Özkütük et al. (2008) , in their study which was detected the efficacy of second-line drugs against MDR M. tuberculosis isolates from our region; found a high susceptibility rate of 95% for OFX used as representative of FQs (8) .
The tests used to detect resistance to second-line TB drugs are mostly difficult, time consuming, expensive, not fully standardized methods, and are generally indicated that to be appropriate evaluating by experienced laboratories. For this reason, although there are numerous studies on the susceptibility of M. tuberculosis to first-line drugs, limited research on susceptibility to FQs and other second-line drugs has been found. In recent years, in addition to standard and reference method "agar proportion method", also used in this study, a number of new phenotypic and genotypic tests that are advantageous in terms of speed, time to completion, cost and ease of use aiming diagnosis of MDR-TB and XDR-TB have been developed. In other respects, although genotypic tests that determine the mutations responsible for resistance have yielded fairly fast and reliable results, these tests have not always been able to identify the phenotypic resistance due to mutations that have not yet been discovered and some different resistance mechanisms (6, 17, 25) .
Currently, FQs are indicated as an alternative to firstline anti-tuberculosis drugs, especially in resistant cases. When the results of this study are evaluated, high FQ susceptibility rates in MDRs and non-MDRs are pleasing, but the resistance rates are also expected to rise in time depend on increased use. For this reason, it is thought that the spread of resistant strains would be controlled rapidly by monitoring the resistance particularly in MDR M. tuberculosis isolates against FQs and second-line alternative drugs, and also developing and acquiring the related rapid, easy, safe methods to a large number of laboratories.
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